Penn Capital Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-3,271
| Closed | -$391K | – | 182 |
|
|
2022
Q4 | $391K | Sell |
3,271
-85
| -3% | -$10.2K | 0.04% | 151 |
|
|
2022
Q3 | $356K | Sell |
3,356
-154
| -4% | -$16.3K | 0.04% | 162 |
|
|
2022
Q2 | $342K | Sell |
3,510
-57
| -2% | -$5.55K | 0.04% | 178 |
|
|
2022
Q1 | $334K | Buy |
3,567
+691
| +24% | +$64.7K | 0.03% | 184 |
|
|
2021
Q4 | $245K | Buy |
2,876
+10
| +0.3% | +$852 | 0.02% | 201 |
|
|
2021
Q3 | $275K | Sell |
2,866
-149
| -5% | -$14.3K | 0.03% | 192 |
|
|
2021
Q2 | $293K | Sell |
3,015
-28
| -0.9% | -$2.72K | 0.03% | 204 |
|
|
2021
Q1 | $296K | Sell |
3,043
-11
| -0.4% | -$1.07K | 0.03% | 199 |
|
|
2020
Q4 | $293K | Sell |
3,054
-19,401
| -86% | -$1.86M | 0.04% | 188 |
|
|
2020
Q3 | $2.22M | Buy |
22,455
+8,062
| +56% | +$797K | 0.28% | 137 |
|
|
2020
Q2 | $1.8M | Buy |
+14,393
| New | +$1.8M | 0.23% | 151 |
|